EyePoint, Inc.

Listed Company

EYPTCIK 0001314102NasdaqNon-AcceleratedSmaller ReportingLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$31.37M

Net Income

$-231.96M

Total Assets

$364.00M

Equity

$306.11M

Shares Out

83.43M

Op. Cash Flow

$-240.11M

Business

EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing sustained intraocular therapeutics for serious retinal diseases using its proprietary Durasert® and bioerodible Durasert E™ delivery technologies. Its main products and candidates include DURAVYU™ (vorolanib in Durasert E™) for wet AMD and DME, EYP-2301 (razuprotafib in Durasert E™), and the approved DEXYCU® product and licensed Durasert®-based products such as YUTIQ®. The company operates clinical development, manufacturing and licensing activities across pipeline, approved-product and technology-licensing programs. It distributes and develops products through global clinical trials, U.S. specialty distribution channels, and out-licenses to regional partners, including agreements covering Greater China and other territories.

Summary from filing dated 2025-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	31	43	46	41	37
Cost of sales	2	4	5	8	8
Research and development	221	133	65	50	29
Sales and marketing	90,000	131,000	12	26	28
General and administrative	52	52	40	35	26
Total operating expenses	275	189	121	141	92
Loss from operations	−243	−146	−75	−100	−55
Interest and other income, net	12	15	7	2	292,000
Interest expense	−33,000	−14,000	−1	—	—
Loss on extinguishment of debt	0	0	−1	−2	2
Total other income, net	12	15	4	−3	−3
Net loss before income taxes	−232	−131	−71	−102	—
Provision for income taxes	−279,000	−90,000	−83,000	—	—
Net loss	−232	−131	−71	−102	−58
Net loss per share - basic	−3.17	−2.32	−1.82	−2.74	−2.03
Net loss per share - diluted	−3.17	−2.32	−1.82	−2.74	−2.03
Weighted average common shares outstanding - basic	73,251	56,298	38,904	37	29
Weighted average common shares outstanding - diluted	73,251	56,298	38,904	37	29
Unrealized gain (loss) on available-for-sale securities	−67,000	164,000	78,000	−55,000	0
Comprehensive income (loss)	−232	−131	−71	−102	−58

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-06-30
Cash and cash equivalents	102	100	281	96	—
Marketable securities	204	271	50	49	—
Accounts and other receivables, net	651,000	607,000	805,000	16	—
Prepaid expenses and other current assets	20	9	9	10	—
Inventory	2	2	4	3	—
Total current assets	329	383	345	173	—
Property and equipment, net	9	8	5	1	—
Operating lease right-of-use assets	20	21	5	6	3
Restricted cash	150,000	150,000	150,000	150,000	—
Other assets	6	6	0	—	—
Total assets	364	418	355	180	—
Accounts payable	10	12	7	6	—
Accrued expenses	24	18	18	16	—
Deferred revenue	0	18	39	1	—
Other current liabilities	2	1	646,000	579,000	—
Total current liabilities	37	49	63	35	—
Deferred revenue - noncurrent	0	11	21	14	—
Operating lease liabilities - noncurrent	21	22	5	6	—
Other noncurrent liabilities	87,000	205,000	0	600,000	—
Total liabilities	58	82	89	84	—
Contingencies (Note 14)	—	—	—	—	—
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding	0	0	0	0	—
Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 82,826,416 and 68,266,005 shares issued and outstanding at December 31, 2025 and 2024, respectively	83,000	68,000	49,000	34,000	—
Additional paid-in capital	1,410	1,208	1,008	767	—
Accumulated deficit	−1,105	−873	−742	−671	—
Accumulated other comprehensive income (loss)	961,000	1	864,000	786,000	—
Total stockholders equity	306	337	266	96	—
Total liabilities and stockholders equity	364	418	355	180	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−232	−131	−71	−102	−58
Depreciation of property and equipment	2	2	—	—	—
Amortization of debt discount and premium and discount on available-for-sale marketable securities	−5	−6	−856,000	−558,000	628,000
Stock-based compensation	28	37	12	14	7
Deferred income tax	279,000	90,000	83,000	—	—
Accounts receivable and other current assets	−11	−244,000	14	−3	−11
Other assets	−113,000	−6	0	—	—
Inventory	492,000	2	−2	−760,000	1
Accounts payable and accrued expenses	5	6	2	1	8
Right-of-use assets and operating lease liabilities	500,000	2	−39,000	69,000	−28,000
Deferred revenue	−29	−31	45	−868,000	−931,000
Other noncurrent liabilities	−33,000	0	—	—	—
Net cash (used in) provided by operating activities	−240	−126	2	−65	−50
Purchases of marketable securities	−252	−398	−55	−139	−33
Sales and maturities of marketable securities	324	183	55	124	0
Purchases of property and equipment	−3	−4	−3	−2	−156,000
Proceeds from sale of property and equipment	155,000	0	—	—	—
Net cash (used in) provided by investing activities	69	−219	−3	−17	−33
Proceeds from issuance of stock	173	163	226	0	—
Payment of equity issue costs	−543,000	−672,000	−451,000	—	—
Net settlement of stock units to satisfy statutory tax withholding	−1	−5	−169,000	−295,000	−150,000
Proceeds from exercise of stock options and employee stock purchase plan	2	6	3	395,000	—
Principal payments on finance lease obligations	−105,000	−105,000	−36,000	−137,000	−146,000
Net cash (used in) provided by financing activities	174	164	187	−690,000	217
Net (decrease) increase in cash, cash equivalents and restricted cash	2	−182	186	−83	134
Lease liability arising from obtaining right-of-use assets	903,000	18	0	—	—
Stock issuance costs	316,000	311,000	325,000	0	294,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro